Analyst Stock Ratings Upgrades

							Get Alert
Sep 10, 2026	OBIOOrchestra BioMed Hldgs	$5.60	78.57%	Marie ThibaultBTIG 67%	10	Previous Neutral Current Buy	Get Alert
Sep 10, 2026	SFNCSimmons First Ntl	$23.16	12.26%	Wood LayKeefe, Bruyette & Woods 78%	26 26	Previous Market Perform Current Outperform	Get Alert
Sep 9, 2026	SMMTSummit Therapeutics	$17.48	43.02%	Faisal KhurshidJefferies 76%	15 25	Previous Hold Current Buy	Get Alert
Sep 9, 2026	UGIUGI	$37.99	13.18%	Julien Dumoulin-SmithJefferies 64%	40 43	Previous Hold Current Buy	Get Alert

Recent Analyst Stock Rating Upgrade News

Stifel Reinstates Buy on TXO Partners, Announces $17 Price Target

Stifel analyst Robert Hodges reinstates TXO Partners (NYSE:TXO) with a Buy and announces $17 price target.

Needham Reiterates Buy on AeroVironment, Maintains $225 Price Target

Needham analyst Austin Bohlig reiterates AeroVironment (NASDAQ:AVAV) with a Buy and maintains $225 price target.

Needham Maintains Buy on Cooper Companies, Lowers Price Target to $73

Needham analyst David Saxon maintains Cooper Companies (NASDAQ:COO) with a Buy and lowers the price target from $86 to $73.

HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Seaport Therapeutics (NASDAQ:SPTX) with a Buy and maintains $50 price target.

HC Wainwright & Co. Maintains Buy on Tyra Biosciences, Lowers Price Target to $30

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Tyra Biosciences (NASDAQ:TYRA) with a Buy and lowers the price target from $45 to $30.

HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and maintains $60 price target.

Stifel Reinstates Hold on Antero Resources, Announces $42 Price Target

Stifel analyst David Deckelbaum reinstates Antero Resources (NYSE:AR) with a Hold and announces $42 price target.

HC Wainwright & Co. Maintains Buy on Pyxis Oncology, Raises Price Target to $8

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Pyxis Oncology (NASDAQ:PYXS) with a Buy and raises the price target from $7 to $8.

Stifel Reinstates Buy on Devon Energy, Announces $61 Price Target

Stifel analyst David Deckelbaum reinstates Devon Energy (NYSE:DVN) with a Buy and announces $61 price target.

HC Wainwright & Co. Maintains Buy on Ocugen, Lowers Price Target to $9.5

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Ocugen (NASDAQ:OCGN) with a Buy and lowers the price target from $10 to $9.5.

The Best Trading Research Platform

For Retail Investors and Professional Trades Alike.

Get Started for Free

Benzinga Pro on Macbook

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved